Judul : Thammasat and Novo Nordisk Collaborate to Boost Clinical Research
link : Thammasat and Novo Nordisk Collaborate to Boost Clinical Research
Thammasat and Novo Nordisk Collaborate to Boost Clinical Research
The Thammasat University Hospital, the Faculty of Medicine at Thammasat University, and Novo Nordisk Pharma (Thailand) Ltd. have entered into a Memorandum of Understanding (MOU) to enhance clinical trials at the hospital, continuing their earlier partnership focused on addressing Diabetes and Obesity. This latest agreement seeks to promote beneficial advancements in the management and treatment of cardio-metabolic conditions within Thailand.
The Memorandum of Understanding, titled "Together Towards Tomorrow: Shaping the Future of Cardio-Metabolic Care Through Clinical Research," was signed at Thammasat University Hospital, a well-known facility situated in the outskirts of Bangkok, representing a major expansion of cooperation between the involved entities. The MOU was signed during a period when Thailand is experiencing an increasing number of people affected by cardio-metabolic conditions—with an estimate that more than 45 percent of Thais are considered overweight or obese and that there are at least 6.1 million individuals living with diabetes in the country. These two non-communicable diseases (NCDs) present not only a substantial public health issue but also a rising economic challenge.
Clinical trials form a fundamental part of the healthcare system. Introducing new therapies and methods of treatment to patients requires careful evaluation of their safety and efficacy. These trials also create benefits throughout the medical field and more—offering patients access to advanced technologies and generating economic advantages through infrastructure growth and the creation of local employment opportunities.
Cardiovascular metabolic disorders are connected conditions, such as obesity, diabetes, heart diseases, metabolic dysfunction-associated steatohepatitis (MASH), and chronic kidney diseases. Clinical studies play a vital role in ensuring safe and effective treatments to address these illnesses before they lead to further complications.
Assoc Prof Dilok Piyayothai, MD, Director of Thammasat University Hospital, stated, 'This MOU marks a significant step forward in our ongoing initiatives to improve cardio metabolic care in Thailand. Our hospital's work on addressing diabetes and obesity has already demonstrated the effectiveness of collaborative research in making a real difference against these two non-communicable diseases. Thammasat University Hospital is confident in enhancing our skills in this area as we enter our fourth decade, with our goal being to deliver improved and safer comprehensive care to the population.'
Associate Professor Auchara Tangsathapornpong, MD, Dean of the Faculty of Medicine at Thammasat University, said, 'There is an immediate need to enhance our understanding via clinical trials to create innovations that tackle these critical cardio metabolic conditions while safeguarding the health of our local communities. By collaborating, we can anticipate a future that is more secure and beneficial for individuals affected by cardio metabolic diseases.'
Mr. Cihan Serdar Kizilcik, the General Manager of Novo Nordisk, stated, "Novo Nordisk highly values research and development, especially in clinical trials, as we are dedicated to advancing innovation for improved health results. From 2020 to 2023, our investment in R&D in Thailand has grown by 25 percent each year. Our investment totaled approximately THB 370 million between 2019 and 2023. When dealing with complex conditions like cardio-metabolic diseases, these clinical trials are essential not only for expanding our collective knowledge but also for ensuring patient safety. We are confident that this collaboration will lead to new innovations that benefit all Thais."
The collaboration between Novo Nordisk and Thammasat University Hospital along with the Faculty of Medicine at Thammasat University is planned to support multiple clinical studies designed to discover more efficient therapies and approaches for individuals dealing with significant medical issues. The entities involved are dedicated to enhancing medical understanding and boosting health results via research grounded in evidence and creative advancements.
Provided by SyndiGate Media Inc. (Syndigate.info).Demikianlah Artikel Thammasat and Novo Nordisk Collaborate to Boost Clinical Research
Anda sekarang membaca artikel Thammasat and Novo Nordisk Collaborate to Boost Clinical Research dengan alamat link https://www.arablionz.pro/2025/11/thammasat-and-novo-nordisk-collaborate.html
0 Response to "Thammasat and Novo Nordisk Collaborate to Boost Clinical Research"
Posting Komentar